Role of AS04 in human papillomavirus vaccine: Mode of action and clinical profile

Expert Opinion on Biological Therapy

Volumn 11, Issue 5, 2011, Pages 667-677

  Garçon, Nathalie ^a   Wettendorff, Martine ^a   Van Mechelen, Marcelle ^a  

^a GLAXOSMITHKLINE BIOLOGICALS   (Belgium)

Author keywords

Adjuvant System; AS04; cervical cancer; HPV; HPV vaccine

Indexed keywords

ALUMINUM HYDROXIDE; ALUMINUM SALT; AS 04; CYTOKINE; GAMMA INTERFERON; HEPATITIS B VACCINE; HERPES SIMPLEX VACCINE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; IMMUNOSTIMULATING AGENT; INTERLEUKIN 6; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MONOCYTE CHEMOTACTIC PROTEIN 1; PHOSPHORYL LIPID A; PLACEBO; TOLL LIKE RECEPTOR; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; WART VIRUS VACCINE;

ANTIGEN PRESENTING CELL; ARTICLE; CELL STIMULATION; CYTOKINE PRODUCTION; DENDRITIC CELL; DRUG ACTIVITY; DRUG EFFICACY; DRUG FORMULATION; DRUG INDICATION; DRUG MECHANISM; DRUG SAFETY; HUMAN; IMMUNOGENICITY; INJECTION SITE REACTION; INNATE IMMUNITY; MONOCYTE; NONHUMAN; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); POSTMARKETING SURVEILLANCE; PROTEIN EXPRESSION; PROTEIN INDUCTION; RANDOMIZED CONTROLLED TRIAL (TOPIC); T LYMPHOCYTE; UTERINE CERVIX CANCER; VERRUCA VULGARIS; VIRUS LIKE AGENT;

ADJUVANTS, IMMUNOLOGIC; ALUMINUM HYDROXIDE; HUMANS; IMMUNITY, INNATE; LIPID A; PAPILLOMAVIRUS VACCINES;

HUMAN PAPILLOMAVIRUS;

EID: 79953870474     PISSN: 14712598     EISSN: None     Source Type: Journal    
DOI: 10.1517/14712598.2011.573624     Document Type: Article

References (83)

1. Matzinger P. The danger model: a renewed sense of self. Science 2002;296:301-5 (Pubitemid 34303674)
2. Guy B. The perfect mix: recent progress in adjuvant research. Nat Rev Microbiol 2007;5:505-17 (Pubitemid 46925379)
3. Garcon N, Chomez P, Van Mechelen M. GlaxoSmithKline adjuvant systems in vaccines: concepts, achievements and perspectives. Expert Rev Vaccines 2007;6:723-39 (Pubitemid 47607848)
4. Dougan G, Hormaeche C. How bacteria and their products provide clues to vaccine and adjuvant development. Vaccine 2006;24(Suppl 2):S2-9
5. Iwasaki A, Medzhitov R. Toll-like receptor control of the adaptive immune responses. Nat Immunol 2004;5:987-95 (Pubitemid 41057715)
6. Medzhitov R, Preston-Hurlburt P, Janeway CA Jr. A human homologue of the Drosophila Toll protein signals activation of adaptive immunity. Nature 1997;388:394-97 (Pubitemid 27334820)
7. Akira S, Uematsu S, Takeuchi O. Pathogen recognition and innate immunity. Cell 2006;124:783-801 (Pubitemid 43261452)
8. Kawai T, Akira S. Signaling to NF-kappaB by Toll-like receptors. Trends Mol Med 2007;13:460-69
9. Pulendran B, Ahmed R. Translating innate immunity into immunological memory: implications for vaccine development. Cell 2006;124:849-63 (Pubitemid 43261457)
10. Burdin N, Guy B, Moingeon P. Immunological foundations to the quest for new vaccine adjuvants. BioDrugs 2004;18:79-93 (Pubitemid 38507891)
11. Pasare C, Medzhitov R Toll pathway-dependent blockade of CD4+CD25+ T cell-mediated suppression by dendritic cells. Science 2003;299:1033-36 (Pubitemid 36222922)
12. Sallusto F, Lanzavecchia A. Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor alpha. J Exp Med 1994;179:1109-18
13. Joffre O, Nolte MA, Sporri R, et al. Inflammatory signals in dendritic cell activation and the induction of adaptive immunity. Immunol Rev 2009;227:234-47
14. Randolph GJ, Jakubzick C, Qu C. Antigen presentation by monocytes and monocyte-derived cells. Curr Opin Immunol 2008;20:52-60
15. van Duin D, Medzhitov R, Shaw AC Triggering TLR signaling in vaccination. Trends Immunol 2006;27:49-55 (Pubitemid 43083564)
16. Meylan E, Tschopp J, Karin M. Intracellular pattern recognition receptors in the host response. Nature 2006;442:39-44 (Pubitemid 44064203)
17. Shi Y, Evans JE, Rock KL. Molecular identification of a danger signal that alerts the immune system to dying cells. Nature 2003;425:516-21 (Pubitemid 37237047)
18. Martinon F, Burns K, Tschopp J. The inflammasome: a molecular platform triggering activation of inflammatory caspases and processing of proIL-beta. Mol Cell 2002;10:417-26 (Pubitemid 35007355)
19. Janeway CA Jr. Approaching the asymptote? Evolution and revolution in immunology. Cold Spring Harb Symp Quant Biol 1989;54(Pt 1):1-13 (Pubitemid 20177564)
20. Brewer JM. (How) do aluminium adjuvants work? Immunol Lett 2006;102:10-15 (Pubitemid 41606034)
21. Glenny AT, Buttle GAH, Stevens MF. Rate of disappearance of diphtheria toxoid injected into rabbits and guinea pigs: toxoid precipitated with alum. J Pathol 1931;34:267-75
22. Ramon G. Procedes pour accroitre la production des antitoxines. Ann Inst Pasteur 1926;40:1-10
23. Hogen Esch H. Mechanisms of stimulation of the immune response by aluminum adjuvants. Vaccine 2002;20(Suppl 3):S34-9 (Pubitemid 34607673)
24. Lindblad EB. Aluminium adjuvants-in retrospect and prospect. Vaccine 2004;22:3658-68
25. Morefield GL, Sokolovska A, Jiang D, et al. Role of aluminum-containing adjuvants in antigen internalization by dendritic cells in vitro. Vaccine 2005;23:1588-95 (Pubitemid 40203396)
26. Kool M, Soullie T, van Nimwegen M, et al. Alum adjuvant boosts adaptive immunity by inducing uric acid and activating inflammatory dendritic cells. J Exp Med 2008;205:869-82 (Pubitemid 351549884)
27. Eisenbarth SC, Colegio OR, O'Connor W, et al. Crucial role for the Nalp3 inflammasome in the immunostimulatory properties of aluminium adjuvants. Nature 2008;453:1122-26 (Pubitemid 351871731)
28. Lambrecht BN, Kool M, Willart MAM, et al. Mechanism of action of clinically approved adjuvants. Curr Opin Immunol 2009;21:23-9
29. Li H, Nookala S, Re F. Aluminum hydroxide adjuvants activate caspase-1 and induce IL-1beta and IL-18 release. J Immunol 2007;178:5271-76 (Pubitemid 46595312)
30. Marrack P, McKee AS, Munks, MW. Towards an understanding of the adjuvant action of aluminium. Nat.Rev. Immunol 2009;9:287-93
31. Reed SG, Bertholet S, Coler RN, et al. New horizons in adjuvants for vaccine development. Trends Immunol 2009;30:23-32
32. Tritto E, Mosca F, De Gregorio E. Mechanism of action of licensed vaccine adjuvants. Vaccine 2009;27:3331-34
33. Hirschfeld M, Ma Y, Weis JH, et al. Cutting edge: repurification of lipopolysaccharide eliminates signaling through both human and murine toll-like receptor 2. J Immunol 2000;165:618-22 (Pubitemid 30484724)
34. Tapping RI, Akashi S, Miyake K, et al. Toll-like receptor 4, but not toll-like receptor 2, is a signaling receptor for Escherichia and Salmonella lipopolysaccharides. J Immunol 2000;165:5780-87
35. Baldridge JR, McGowan P, Evans JT, et al. Taking a Toll on human disease: Toll-like receptor 4 agonists as vaccine adjuvants and monotherapeutic agents. Expert Opin Biol Ther 2004;4:1129-38 (Pubitemid 38937554)
36. Casella CR, Mitchell TC. Putting endotoxin to work for us: monophosphoryl lipid A as a safe and effective vaccine adjuvant. Cell Mol Life Sci 2008;65:3231-40
37. Qureshi N, Takayama K, Ribi E. Purification and structural determination of nontoxic lipid A obtained from the lipopolysaccharide of Salmonella typhimurium. J Biol Chem 1982;257:11808-15 (Pubitemid 13218648)
38. Ismaili J, Rennesson J, Aksoy E, et al. Monophosphoryl lipid A activates both human dendritic cells and T cells. J Immunol 2002;168:926-32 (Pubitemid 34049597)
39. Martin M, Michalek SM, Katz J. Role of innate immune factors in the adjuvant activity of monophosphoryl lipid A. Infect Immun 2003;71:2498-507 (Pubitemid 36519862)
40. Harper DM, Franco EL, Wheeler C, et al. Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial. Lancet 2004;364:1757-65 (Pubitemid 39488060)
41. Paavonen J, Naud P, Salmeron J, et al. Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women. Lancet 2009;374:301-14
42. Kundi M. New hepatitis B vaccine formulated with an improved adjuvant system. Expert Rev Vaccines 2007;6:133-40 (Pubitemid 46607449)
43. Garcon N, Van Mechelen M, Wettendorff M. Development and evaluation of AS04, a novel and improved immunological adjuvant system containing MPL and aluminium salt. In: Schijns V, O'Hagan D, editors, Immunopotentiators in Modern Vaccines. Elsevier Academic Press, London; 2006. p. 161-77
44. Bosch FX, Burchell AN, Schiffman M, et al. Epidemiology and natural history of human papillomavirus infections and type-specific implications in cervical neoplasia. Vaccine 2008;26(Suppl 10):K1-16
45. Liaw KL, Hildesheim A, Burk RD, et al. A prospective study of human papillomavirus (HPV) type 16 DNA detection by polymerase chain reaction and its association with acquisition and persistence of other HPV types. J Infect Dis 2001;183:8-15 (Pubitemid 32043036)
46. Parkin DM, Bray F, Ferlay J, et al. Global cancer statistics, 2002. CA Cancer J Clin 2005;55:74-108
47. Schiffman M, Herrero R, Desalle R, et al. The carcinogenicity of human papillomavirus types reflects viral evolution. Virology 2005;337:76-84 (Pubitemid 40725441)
48. de Villiers EM, Fauquet C, Broker TR, et al. Classification of papillomaviruses. Virology 2004;324:17-27 (Pubitemid 38737395)
49. Jenkins D. A review of cross-protection against oncogenic HPV by an HPV-16/18 AS04-adjuvanted cervical cancer vaccine: importance of virological and clinical endpoints and implications for mass vaccination in cervical cancer prevention. Gynecol Oncol 2008;110:S18-25
50. Parkin DM, Bray F. Chapter 2: the burden of HPV-related cancers. Vaccine 2006;24:S11-25 (Pubitemid 44404053)
51. Munoz N, Bosch FX, Castellsague X, et al. Against which human papillomavirus types shall we vaccinate and screen? The international perspective. Int J Cancer 2004;111:278-85 (Pubitemid 38924707)
52. Doorbar J. The papillomavirus life cycle. J Clin Virol 2005;32(Suppl 1):S7-15
53. Munger K, Howley PM. Human papillomavirus immortalization and transformation functions. Virus Res 2002;89:213-28 (Pubitemid 35351540)
54. Passmore J-AS, Milner M, Denny L, et al. Comparison of cervical and blood T-cell responses to human papillomavirus-16 in women with human papillomavirus-associated cervical intraepithelial neoplasia. Immunology 2006;119:507-14 (Pubitemid 44722213)
55. Ho GY, Studentsov YY, Bierman R, et al. Natural history of human papillomavirus type 16 virus-like particle antibodies in young women. Cancer Epidemiol Biomarkers Prev 2004;13:110-16 (Pubitemid 38116628)
56. Ressing ME, van Driel WJ, Celis E, et al. Occasional memory cytotoxic T-cell responses of patients with human papillomavirus type 16-positive cervical lesions against a human leukocyte antigen-A *0201-restricted E7-encoded epitope. Cancer Res 1996;56:582-8
57. Breitburd F, Kirnbauer R, Hubbert NL, et al. Immunization with viruslike particles from cottontail rabbit papillomavirus (CRPV) can protect against experimental CRPV infection. J Virol 1995;69:3959-63
58. Christensen ND, Reed CA, Cladel NM, et al. Immunization with viruslike particles induces long-term protection of rabbits against challenge with cottontail rabbit papillomavirus. J Virol 1996;70:960-5 (Pubitemid 26029013)
59. Suzich JA, Ghim S-J, Palmer-Hill FJ, et al. Systemic immunization with papillomavirus L1 protein completely prevents the development of viral mucosal papillomas. Proc Natl Acad Sci USA 1995;92:11553-57 (Pubitemid 26014152)
60. Schwarz TF, Leo O. Immune response to human papillomavirus after prophylactic vaccination with AS04-adjuvanted HPV-16/18 vaccine: improving upon nature. Gynecol Oncol 2008;110:S1-10
61. Kirnbauer R, Booy F, Cheng N, et al. Papillomavirus L1 major capsid protein self-assembles into virus-like particles that are highly immunogenic Proc Natl Acad Sci USA 1992;89:12180-84 (Pubitemid 23004809)
62. Giannini SL, Hanon E, Moris P, et al. Enhanced humoral and memory B cellular immunity using HPV16/18 L1 VLP vaccine formulated with the MPL/aluminium salt combination (AS04) compared to aluminium salt only. Vaccine 2006;24:5937-49 (Pubitemid 44080367)
63. Didierlaurent AM, Morel S, Lockman L, et al. AS04, an Aluminum Salt-and TLR-4 agonist-based adjuvant system, induces a transient localized innate immune response leading to enhanced adaptive immunity. J Immunol 2009;183:6186-97
64. Fazilleau N, Mark L, Heyzer-Williams LJ, et al. Follicular helper T cells: lineage and location. Immunity 2009;30:324-35
65. Malherbe L, Mark L, Fazilleau N, et al. Vaccine adjuvants alter TCR-based selection thresholds. Immunity 2008;28:698-709
66. Fazilleau N, Heyzer-Williams LJ, Rosen H, et al. The function of follicular helper T cells is regulated by the strength of T cell antigen receptor binding. Nat Immunol 2009;10:375-84
67. Ruprecht CR, Lanzavecchia, A. Toll-like receptor stimulation as a third signal required for activation of human naive B cells. Eur J Immunol 2006;36:810-16
68. Bernasconi NL, Traggiai E, Lanzavecchia A. Maintenance of serological memory by polyclonal activation of human memory B cells. Science 2002;298:2199-202 (Pubitemid 35471246)
69. Bourke E, Bosisio D, Golay J, et al. The toll-like receptor repertoire of human B lymphocytes: inducible and selective expression of TLR9 and TLR10 in normal and transformed cells. Blood 2003;102:956-63 (Pubitemid 36917790)
70. Colonna M. Toll-like receptors and IFN-alpha: partners in autoimmunity. J Clin Invest 2006;116:2319-22 (Pubitemid 44330127)
71. Marshak-Rothstein A. Toll-like receptors in systemic autoimmune disease. Nat Rev Immunol 2006;6:823-35 (Pubitemid 44631651)
72. Zanin-Zhorov A, Tal-Lapidot G, Cahalon L, et al. Cutting edge: T cells respond to lipopolysaccharide innately via TLR4 signaling. J Immunol 2007;179:41-4 (Pubitemid 46986515)
73. Pasare C, Medzhitov R Control of B-cell responses by Toll-like receptors. Nature 2005;438:364-68 (Pubitemid 41643953)
74. Schwarz T, Rivera M, Valencia A, et al. Long-term safety and immunogenicity of a human papillomavirus (HPV)-16/18 AS04-adjuvanted cervical cancer vaccine in girls aged 10-14 years: 36-month follow-up. Pediatr Infect Dis J 2009;28:e197
75. Romanowski B, de Borba PC, Naud PS, et al. Sustained efficacy and immunogenicity of the human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine: analysis of a randomised placebo-controlled trial up to 6.4 years. Lancet 2009;374:1975-85
76. Pedersen C, Petaja T, Strauss G, et al. Immunization of early adolescent females with human papillomavirus type 16 and 18 L1 virus-like particle vaccine containing AS04 adjuvant. J Adolesc Health 2007;40:564-71 (Pubitemid 46771257)
77. Schwarz TF, Spaczynski M, Schneider A, et al. Immunogenicity and tolerability of an HPV-16/18 AS04-adjuvanted prophylactic cervical cancer vaccine in women aged 15-55 years. Vaccine 2009;27:581-87
78. Einstein MH, Baron M, Levin MJ, et al. Comparison of the immunogenicity and safety of Cervarix™ and Gardasil® human papillomavirus (HPV) cervical cancer vaccines in healthy women aged 18-45 years. Hum Vaccin 2009;5:705-19
79. Harper DM, Franco EL, Wheeler CM, et al. Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial. Lancet 2006;367:1247-55
80. Paavonen J, Jenkins D, Bosch FX, et al. Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial. Lancet 2007;369:2161-70 (Pubitemid 46977438)
81. Brown DR, Kjaer SK, Sigurdsson K, et al. The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in generally HPV-naive women aged 16-26 years. J Infect Dis 2009;199:926-35
82. Descamps D, Hardt K, Spiessens B, et al. Safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine for cervical cancer prevention: a pooled analysis of 11 clinical trials. Hum Vaccin 2009;5:332-40
83. Verstraeten T, Descamps D, David MP, et al. Analysis of adverse events of potential autoimmune aetiology in a large integrated safety database of AS04 adjuvanted vaccines. Vaccine 2008;26:6630-8